37th Pezcoller Symposium
June 22-23, 2026
Humanities Department, University of Trento, Italy
Cancer Evolutionary Trajectories: emerging principles and therapeutic implications
FOCUS & GOALS of the 2026 Symposium
The conversion of a normal cell to a malignant cell is the result of clonal evolution occurring over a timescale measured in years, in contrast to mammalian evolution, which occurs over millennia. The selection pressures arising from host factors (e.g. the immune system), as well as therapeutics, profoundly influence cancer evolution, which in turn influences clinical outcomes. Cancer evolution is accelerated, at least partly, by the clonal diversity created by intratumoral genetic and epigenic heterogeneity.
The 2026 Pezcoller Symposium will bring together experts who have used cutting edge technologies to measure cancer evolution and tumor heterogeneity and its biological consequences, as well as investigators who have made significant advances in our understanding of how cancer evolution is influenced by germline genetics and environmental factors.
PROGRAM
OPPORTUNITIES FOR YOUNG RESEARCHERS
Great importance is given to young researchers, who are invited to submit an abstract of their research project to the Evaluation Committee, for presenting it during the Poster Session.
Best Poster Lectures: the authors of the top 3 selected abstracts are invited to present their research in front of the plenary session of the Symposium.
Moreover, the authors of the best posters may be eligible for the Pezcoller-Begnudelli Award, the EACR-AACR-Mark Foundation Best Abstract Prizes and the EMBO Poster Prize.
Faculty
Keynote Speaker
CHARLES SWANTON
PhD
The Francis Crick Institute
London, UK
Keynote Speaker
HANS CLEVERS
MD, PhD
Utrecht University
Utrecht, Netherlands
ANDREA BALLABIO
MD
Telethon Institute of Genetics and Medicine (TIGEM)
University “Federico II”
Naples, Italy
BEATRICE BODEGA
PhD
National Institute of Molecular Genetics (INGM)
Milan, Italy
KATHLEEN H. BURNS
MD, PhD
Dana Farber Cancer Institute Boston, MA
SARAH-MARIA FENDT
PhD
VIB–KU Leuven Center for Cancer Biology
Leuven, Belgium
DAN-AVI LANDAU
MD, PhD
Weill Cornell Medicine,
New York Genome Center
New York, NY
SHERENE LOI
MD, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia
FRANZISKA MICHOR
PhD
Dana Farber Cancer Institute Boston, MA
Harvard University
Cambridge, MA
KORNELIA POLYAK
MD, PhD
Dana Farber Cancer Institute Boston, MA
Harvard University
Cambridge, MA
COLINDA SCHEELE
PhD
VIB–KU Leuven Center for Cancer Biology
Leuven, Belgium
DANIEL SCHRAMEK
PhD
Lunenfeld-Tanenbaum
Research Institute
Toronto, Canada
ANDREA SOTTORIVA
PhD
Human Technopole
Milan, Italy
SAMRA TURAJLIC
MD, PhD
The Francis Crick Institute
London, UK
ANDREA VENTURA
MD, PhD
Memorial Sloan Kettering
Cancer Center
New York, NY
JONATHAN S. WEISSMAN
PhD
Whitehead Institute at MIT
Cambridge, MA

